TrialPath
Type 2 diabetes · Chicago

Type 2 diabetes clinical trials in Chicago

20 recruiting type 2 diabetes studies within range of Chicago. Click any trial for full eligibility criteria and contact info.

Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

Recruiting

This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.

PhaseNA
TypeInterventional
Age14 Years – 75 Years
WhereLos Angeles, California, United States + 10 more
SponsorInsulet Corporation
▾Tap for details
Apply

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

NCT06112418 · Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Recruiting

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.

PhaseNA
TypeInterventional
Age55 Years
WhereChandler, Arizona, United States + 124 more
SponsorCleerly, Inc.
▾Tap for details
Apply

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484 · Type 2 Diabetes, Cortisol Excess
Recruiting

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

PhasePhase 2
TypeInterventional
Age18 Years
WhereChandler, Arizona, United States + 60 more
SponsorSparrow Pharmaceuticals
▾Tap for details

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473 · Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Recruiting

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.

PhasePhase 3
TypeInterventional
Age18 Years
WhereAnniston, Alabama, United States + 1141 more
SponsorBoehringer Ingelheim
▾Tap for details
Apply

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725 · Obesity or Overweight
Recruiting

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

PhasePhase 3
TypeInterventional
Age18 Years
WhereDothan, Alabama, United States + 219 more
SponsorAstraZeneca
▾Tap for details
Apply

A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

NCT04786262 · Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Recruiting

This study will evaluate the safety, tolerability and efficacy of VX-880 infusion and VX-017 infusion in participants with type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.

PhasePhase 3
TypeInterventional
Age18 Years – 65 Years
WhereDuarte, California, United States + 28 more
SponsorVertex Pharmaceuticals Incorporated
▾Tap for details
Apply

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954 · Diabetes Mellitus, Type 2
Recruiting

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereLancaster, California, United States + 62 more
SponsorNovo Nordisk A/S
▾Tap for details
Apply

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190 · Overweight, Obesity
Recruiting

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

PhasePhase 3
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 184 more
SponsorEli Lilly and Company
▾Tap for details
Apply

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

NCT07271186 · Diabetic Kidney Disease (DKD)
Recruiting

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WhereHuntsville, Alabama, United States + 58 more
SponsorRegeneron Pharmaceuticals
▾Tap for details
Apply

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

NCT07595549 · Obesity, Overweight and/or Obesity, Overweight
Recruiting

The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. Berobenatide or placebo is given by a shot under the skin in the belly area. The objective of the study is to compare the experiences of people receiving berobenatide to those of the people who do not to assess if the study medicine is effective and safe. People will take part in this study for about 20 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.

PhasePhase 3
TypeInterventional
Age18 Years
WhereCanoga Park, California, United States + 79 more
SponsorPfizer
▾Tap for details
Apply

Diabetic Neuropathy in Spinal Cord Stimulator Patients

NCT04687215 · Diabetes Mellitus, Neuropathy, Neuropathic Pain
Recruiting

The objective of this study is to assess the effect Spinal Cord Stimulators have toward improving vascular changes of diabetes mellitus in patients eligible for SCS placement based on their condition of painful diabetic neuropathy; we will evaluate improving their disability and quality of life, improving micro-circulatory changes induced by Diabetes Mellitus (DM), improving macro-circulatory changes induced by DM and improving arterial stiffness of the vessels of the lower extremity.

Phase—
TypeObservational
Age18 Years
WhereChicago, Illinois, United States
SponsorUniversity of Chicago
▾Tap for details
Apply

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

NCT06964087 · Type I Diabetes
Recruiting

This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.

PhasePhase 2
TypeInterventional
Age18 Years – 50 Years
WhereBirmingham, Alabama, United States + 4 more
SponsorOp-T LLC
▾Tap for details
Apply

Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes

NCT07650682 · Type 2 Diabetes, Insulin Dependent Diabetes
Recruiting

This observational study aims to collect detailed metabolic and physiologic data from adults with insulin-dependent type 2 diabetes mellitus following consumption of a mixed meal tolerance test. Participants will undergo frequent blood sampling over a 4-hour period after consuming a standardized liquid mixed meal to measure glucose, insulin, glucagon, C-peptide, and triglyceride responses. Participants will also use continuous glucose monitoring and wearable physical activity tracking devices during free-living conditions. The purpose of this study is to develop mathematical models and digital representations ("digital twins") of people with type 2 diabetes mellitus. These models may help researchers better understand metabolic responses to meals, physical activity, and diabetes treatments, and may support future development of personalized diabetes technologies and therapies.

Phase—
TypeObservational
Age18 Years – 65 Years
WhereChicago, Illinois, United States
SponsorClinical Nutrition Research Center, Illinois Institute of Technology
▾Tap for details
Apply

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Recruiting

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).

PhasePhase 3
TypeInterventional
Age18 Years
WhereSun City, Arizona, United States + 185 more
SponsorAstraZeneca
▾Tap for details
Apply

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

NCT07527650 · Type 2 Diabetes Mellitus, T2DM
Recruiting

This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereMesa, Arizona, United States + 19 more
SponsorHanmi Pharmaceutical Company Limited
▾Tap for details
Apply

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

NCT06739122 · Type 2 Diabetes
Recruiting

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

PhasePhase 3
TypeInterventional
Age10 Years – 17 Years
WhereTucson, Arizona, United States + 50 more
SponsorEli Lilly and Company
▾Tap for details
Apply

A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants

NCT07024823 · Chronic Kidney Disease
Recruiting

This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD), and the effect of multiple doses of AZD4248 on the PK of oral midazolam and metformin.

PhasePhase 1
TypeInterventional
Age18 Years – 75 Years
WhereGlendale, California, United States + 4 more
SponsorAstraZeneca
▾Tap for details
Apply

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

NCT07776509 · Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
Recruiting

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.

PhasePhase 3
TypeInterventional
Age18 Years
WhereEscondido, California, United States + 95 more
SponsorAstraZeneca
▾Tap for details
Apply

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07564414 · Obesity, Type 2 Diabetes
Recruiting

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

PhasePhase 3
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 302 more
SponsorNovo Nordisk A/S
▾Tap for details
Apply

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335 · Type 2 Diabetes, Cardiovascular Risk
Recruiting

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.

PhasePhase 3
TypeInterventional
Age45 Years
WhereBirmingham, Alabama, United States + 329 more
SponsorNovo Nordisk A/S
▾Tap for details
Apply